168 related articles for article (PubMed ID: 8396956)
1. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.
Stiekema JC; Van Griensven JM; Van Dinther TG; Cohen AF
Br J Clin Pharmacol; 1993 Jul; 36(1):51-6. PubMed ID: 8396956
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof M; de Boer A; Magnani HN; Stiekema JC
Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
Ofosu FA
Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
[TBL] [Abstract][Full Text] [Related]
4. Orgaran (Org 10172): its pharmacological profile in experimental models.
Meuleman DG
Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
[TBL] [Abstract][Full Text] [Related]
5. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
[TBL] [Abstract][Full Text] [Related]
6. Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan (Org 10172) by protamine chloride.
Stiekema JC; Wijnand HP; ten Cate H; ten Cate JW; Harenberg J; Egberts JF; van Dinther TG
Thromb Res; 1991 Jul; 63(1):157-67. PubMed ID: 1948817
[TBL] [Abstract][Full Text] [Related]
7. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
8. [Heparin-induced thrombopenia during hemodialysis in intensive care: use of a low molecular weight heparinoid, ORG 10172 (Orgaran)].
Mahul P; Raynaud J; Favre JP; Jospé R; Décousus H; Auboyer C
Ann Fr Anesth Reanim; 1995; 14(1):29-32. PubMed ID: 7677282
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of low molecular weight heparins.
Bara L; Samama M
Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans.
Visser A; Meuleman DG
Thromb Res; 1990 Jun; 58(5):469-79. PubMed ID: 2164263
[TBL] [Abstract][Full Text] [Related]
12. Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).
Andrassy K; Mörike K; Koderisch J; Weber E
Thromb Res; 1988 Mar; 49(6):601-11. PubMed ID: 3164530
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne KR; McMahon LP; Becker GJ
Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
15. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.
Greinacher A; Drost W; Michels I; Leitl J; Gottsmann M; Kohl HJ; Glaser M; Mueller-Eckhardt C
Ann Hematol; 1992 Jan; 64(1):40-2. PubMed ID: 1310879
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
[TBL] [Abstract][Full Text] [Related]
17. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
[TBL] [Abstract][Full Text] [Related]
18. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.
Bradbrook ID; Magnani HN; Moelker HC; Morrison PJ; Robinson J; Rogers HJ; Spector RG; Van Dinther T; Wijnand H
Br J Clin Pharmacol; 1987 Jun; 23(6):667-75. PubMed ID: 3606928
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers.
Andrassy K; Eschenfelder V; Koderisch J; Weber E
Thromb Res; 1994 Jan; 73(2):95-108. PubMed ID: 7802862
[TBL] [Abstract][Full Text] [Related]
20. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
